AL Amyloidosis
67
22
30
21
Key Insights
Highlights
Success Rate
78% trial completion
Published Results
11 trials with published results (16%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
9.0%
6 terminated out of 67 trials
77.8%
-8.8% vs benchmark
9%
6 trials in Phase 3/4
52%
11 of 21 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 21 completed trials
Clinical Trials (67)
BCMA/GPRC5D Trispecific Antibody Treatment for Newly Diagnosed Amyloidosis (AL-004)
Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis
A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL).
A Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL Amyloidosis
The Norwegian Immunotherapy in Multiple Myeloma Study
A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis
Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis
Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis
Hungarian National Systemic Amyloidosis Registry
Optimize First-line Treatment for AL Amyloidosis With t (11; 14)
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)
Evaluation of Skin Tests in Biotherapy Allergies
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)
Autologous BCMA-targeted CAR-T Cell Injection for Relapsed/Refractory Light Chain Amyloidosis
Early Detection of Amyloidosis in Monoclonal Gammopathy Using Nuclear Medicine Imaging
A Pilot Study of Anselamimab in Patients With AL Amyloidoma and Measurable Tissue Involvement
Towards Effective, Patient-tailored Anti-plasma Cell Therapies in AL Amyloidosis: Predicting Drug Response and Overcoming Drug Resistance
Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
One Gene, Two Diseases: the Pathologic Role of IGLV1-44 in AL Amyloidosis and POEMS
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis